FDA Boxed Warning for Botulinum Toxin Products

被引：0

|

作者：

不详

机构：

来源：

JOURNAL OF DRUGS IN DERMATOLOGY | 2009年 / 8卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

收藏

页码：595 / 596

页数：2

相关论文

共 50 条

[1] US FDA removes boxed warning from canagliflozin products
Reactions Weekly, 2020, 1820 (1) : 5 - 5
[2] US FDA votes for ban or boxed warning on paracetamol combination products
Reactions Weekly, 2009, 1260 (1) : 2 - 2
[3] FDA approves Multaq with a boxed warning
Reactions Weekly, 2009, 1260 (1) : 3 - 3
[4] FDA Assigns Boxed Warning To Montelukast
Passi, Gouri Rao
INDIAN PEDIATRICS, 2020, 57 (04) : 381 - 381
[5] FDA in favour of boxed warning for Xolair
Reactions Weekly, 2007, 1141 (1) : 4 - 4
[6] FDA Calls for Boxed Warning for Metoclopramide
Lang, Les
GASTROENTEROLOGY, 2009, 136 (07) : 2039 - 2039
[7] A Boxed Warning for Montelukast: The FDA Perspective
Clarridge, Katherine
Chin, Stacy
Eworuke, Efe
Seymour, Sally
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (07): : 2638 - 2641
[8] FDA requires boxed warning for all immediate-release opioid products
Thompson, Cheryl A.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (09) : E114 - E115
[9] FDA boxed warning of anaphylaxis risk with Xolair
Reactions Weekly, 2007, 1159 (1) : 2 - 2
[10] Depot medoxyprogesterone: impact of FDA boxed warning
Reactions Weekly, 2017, 1655 (1) : 8 - 8

← 1 2 3 4 5 →